Clinical-stage pharmaceutical company Visus Therapeutics has signed a licensing agreement for the development and commercialisation of its pupil-modulating eye drops with Zhaoke Ophthalmology. Under the terms of the agreement, Zhaoke will be responsible for clinical development, regulatory approval and commercialisation of Visus’ Brimochol PF and Carbachol PF in Greater China, South Korea and select Southeast […]
Menu ≡ ╳ 
